Hematoma, Subdural, Chronic
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
StrykerPlacement of burr-hole covers
Nielsen BioSciencesPerindopril
Clinical Trials (2)
Total enrollment: 130 patients across 2 trials
Covers to Improve Esthetic Outcome After Surgery for Chronic Subdural Hematoma
Start: Jan 2019Est. completion: Jan 202283 patients
N/ACompleted
Chronic Subdural Hematoma - Reduction of Recurrence by Treatment With Angiotensin Converting Enzyme Inhibitors
Start: Jul 2009Est. completion: Jun 201247 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Small Molecule is the dominant modality (100% of programs)
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.